Aadi Bioscience (NASDAQ:AADI) Trading Up 1.1% – Should You Buy?

Aadi Bioscience, Inc. (NASDAQ:AADI)’s stock price shot up 1.1% on Thursday . The company traded as high as $1.92 and last traded at $1.88. 25,278 shares traded hands during trading, a decline of 90% from the average session volume of 253,080 shares. The stock had previously closed at $1.86.

Aadi Bioscience Stock Up 1.1%

The stock has a 50 day moving average of $1.79 and a 200 day moving average of $2.23. The firm has a market cap of $46.43 million, a price-to-earnings ratio of -0.82 and a beta of 0.68.

Hedge Funds Weigh In On Aadi Bioscience

A number of institutional investors have recently modified their holdings of the business. Two Sigma Advisers LP boosted its stake in Aadi Bioscience by 95.2% in the fourth quarter. Two Sigma Advisers LP now owns 61,686 shares of the company’s stock valued at $195,000 after buying an additional 30,086 shares in the last quarter. Two Sigma Investments LP raised its stake in Aadi Bioscience by 305.2% during the fourth quarter. Two Sigma Investments LP now owns 68,555 shares of the company’s stock worth $216,000 after acquiring an additional 51,638 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of Aadi Bioscience by 33.1% in the fourth quarter. Northern Trust Corp now owns 91,151 shares of the company’s stock worth $288,000 after acquiring an additional 22,677 shares during the last quarter. Bridgeway Capital Management LLC lifted its holdings in shares of Aadi Bioscience by 23.7% in the fourth quarter. Bridgeway Capital Management LLC now owns 115,400 shares of the company’s stock worth $364,000 after acquiring an additional 22,100 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Aadi Bioscience by 4.1% in the 4th quarter. Geode Capital Management LLC now owns 217,294 shares of the company’s stock valued at $686,000 after purchasing an additional 8,546 shares in the last quarter. Institutional investors and hedge funds own 52.08% of the company’s stock.

Aadi Bioscience Company Profile

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.